US Prix Galien 2008 for Selzentry and Isentress
This article was originally published in Scrip
Two HIV medicines,Pfizer's Selzentry (maraviroc) andMerck & Co's Isentress (raltegravir) have been jointly awarded the Prix Galien USA 2008 in the best pharmaceutical agent (small molecule) category.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.